Cocrystal Pharma Advances Antiviral Drug Development
Company Announcements

Cocrystal Pharma Advances Antiviral Drug Development

Cocrystal Pharma ( (COCP) ) has issued an announcement.

Cocrystal Pharma, Inc. is leveraging its innovative, structure-based drug discovery platform to develop groundbreaking antiviral therapeutics targeting influenza, coronaviruses, and noroviruses. With its antiviral candidate CC-42344 showing promise against avian influenza strains resistant to current treatments, and an oral protease inhibitor CDI-988 under clinical evaluation, Cocrystal aims to address the unmet need for effective treatments as seasonal and pandemic viruses continue to evolve. Utilizing Nobel Prize-winning technology, the company is poised to offer rapid, cost-effective solutions in the antiviral market.

For detailed information about COCP stock, go to TipRanks’ Stock Analysis page.

Related Articles
Brian AndersonCocrystal Pharma (COCP) Q3 Earnings Cheat Sheet
TheFlyCocrystal Pharma highlights approach to antiviral drug candidates
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App